Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-10: Teclistamab PK Comparability in Relapsed/Refractory Multiple Myeloma
NCT06425991Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, randomised, open-label trial of teclistamab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration, Area Under Serum Concentration Versus Time Curve and 1 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06425991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425991.